MedTrace Logo

Clinical Study to Assess Safety, PK and PD Parameters of CDR132L

NCT04045405 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-01-09

No results posted yet for this study

Summary

This is a Phase I, randomized, double-blind, placebo-controlled study to assess safety, pharmacokinetics and pharmacodynamic parameters of CDR132L in patients with stable heart failure of ischemic origin (NYHA 1-3).

Conditions

Interventions

DRUG

CDR132L

i.v. administration

Sponsors & Collaborators

  • Cardior Pharmaceuticals GmbH

    lead INDUSTRY

Principal Investigators

  • Wilfried Hauke, MD MFPM · Cardior Pharmaceuticals GmbH CMO

  • Jorg Taubel, MD FFPM · Richmond Pharmacology Ltd CEO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-21
Primary Completion
2020-01-31
Completion
2020-06-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04045405 on ClinicalTrials.gov